Bactiguard Holding AB (SE:BACTI.B)
:BACTI.B
Top Page
Bactiguard Holding AB
(BACTI.B)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr16.00
▼(-17.10% Downside)
Action:ReiteratedDate:03/03/26
The score is held back primarily by still-negative profitability and uneven cash-flow generation despite improving EBITDA. Technicals add caution due to a broader downtrend (below key moving averages and negative MACD), while valuation is not supportive given negative earnings and no dividend yield data.
Positive Factors
Proprietary BIP technology & licensing
Bactiguard’s proprietary BIP coating and dual revenue model (product sales plus licensing) create a durable competitive advantage. Licensing provides scalable, royalty-like revenue as partners commercialize devices, while the coating’s infection-prevention focus aligns with long-term hospital procurement priorities.
Negative Factors
Persisting net losses
Despite EBITDA gains, negative operating profit and net margins persist, keeping returns on equity negative. Ongoing bottom-line losses can erode the capital base over time, force dilutive financings or higher leverage, and constrain strategic initiatives if profitability is not sustained.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary BIP technology & licensing
Bactiguard’s proprietary BIP coating and dual revenue model (product sales plus licensing) create a durable competitive advantage. Licensing provides scalable, royalty-like revenue as partners commercialize devices, while the coating’s infection-prevention focus aligns with long-term hospital procurement priorities.
Read all positive factors
Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr578.22M
Dividend YieldN/A
Average Volume (3M)77.61K
Price to Earnings (P/E)13.9
Beta (1Y)0.13
Revenue Growth-8.10%
EPS Growth62.08%
CountrySE
Employees147
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,043,884
10 Day Avg. Volume120,571
30 Day Avg. Volume77,614
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)kr223.31M
Bactiguard Holding AB Business Overview & Revenue Model
Company Description
Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally. Its infection prevention solutions reduce the risk of healthcare associated infections a...
How the Company Makes Money
Bactiguard generates revenue through the sale of its infection prevention products and coatings to hospitals and healthcare providers worldwide. The company's revenue model is primarily based on direct sales of its medical devices, which incorpora...
Bactiguard Holding AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 215.92M | 243.68M | 203.99M | 223.56M | 169.49M |
| Gross Profit | 184.65M | 207.71M | 139.98M | 180.14M | 130.80M |
| EBITDA | 45.15M | 24.99M | -89.98M | -543.00K | -5.94M |
| Net Income | -7.84M | -29.82M | -138.38M | -52.88M | -58.77M |
Balance Sheet | |||||
| Total Assets | 545.06M | 655.91M | 662.17M | 807.70M | 849.29M |
| Cash, Cash Equivalents and Short-Term Investments | 44.26M | 116.73M | 123.22M | 197.73M | 217.59M |
| Total Debt | 162.92M | 227.77M | 233.10M | 238.70M | 247.96M |
| Total Liabilities | 230.13M | 327.57M | 309.00M | 311.99M | 307.84M |
| Stockholders Equity | 314.93M | 328.34M | 353.18M | 495.71M | 541.45M |
Cash Flow | |||||
| Free Cash Flow | -7.21M | 10.21M | -60.94M | -7.86M | -38.00K |
| Operating Cash Flow | -1.49M | 24.99M | -52.33M | 3.06M | 7.26M |
| Investing Cash Flow | -5.72M | -14.78M | -8.61M | -10.92M | -7.29M |
| Financing Cash Flow | -62.74M | -21.20M | -11.84M | -13.89M | 205.83M |
Bactiguard Holding AB Technical Analysis
Positive
19.30
Price Trends
16.17
Positive
16.74
Negative
21.14
Negative
Market Momentum
0.09
Negative
53.01
Neutral
52.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Positive. The current price of 19.3 is above the 20-day moving average (MA) of 16.21, above the 50-day MA of 16.17, and below the 200-day MA of 21.14, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 53.01 is Neutral, neither overbought nor oversold. The STOCH value of 52.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | kr881.32M | 103.06 | 6.93% | ― | -5.80% | -65.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr650.87M | -4.95 | -36.55% | ― | 62.24% | 21.16% | |
46 Neutral | kr578.22M | 13.94 | -2.52% | ― | -8.10% | 62.08% | |
44 Neutral | kr867.21M | -17.24 | -4.42% | ― | 13.48% | 28.98% | |
42 Neutral | kr195.74M | -5.27 | -18.55% | ― | 0.62% | -82.70% |
* Healthcare Sector Average
SE:BACTI.B
Bactiguard Holding AB
16.50
-13.50
-45.00%
SE:SEZI
Senzime AB
4.14
-0.93
-18.34%
SE:CRAD.B
C-Rad AB Class B
26.10
-2.95
-10.15%
SE:INTEG.B
Integrum AB Class B
7.34
-9.30
-55.88%
SE:SEDANA
Sedana Medical AB
8.73
-0.12
-1.36%
Bactiguard Holding AB Corporate Events
Bactiguard Delivers Strong Q4 as License Focus and Hydrocyn Growth Offset Weaker 2025 Sales
Feb 5, 2026
Bactiguard ended 2025 with a notably strong fourth quarter, posting a return to operating profit and higher EBITDA despite a full-year decline in revenue driven by currency headwinds and discontinued product lines. License revenues were stable exc...
Bactiguard Revises Zimmer Biomet Trauma Deal and Recaptures Global Rights Outside Key Markets
Dec 19, 2025
Bactiguard has revised its trauma license agreement with orthopedic specialist Zimmer Biomet, granting the US group non-exclusive rights to continue commercializing the ZNN Bactiguard-coated trauma nail system in Europe, selected markets in the Mi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.